These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1102 related articles for article (PubMed ID: 18381383)
1. Characteristics of KIT-negative gastrointestinal stromal tumours and diagnostic utility of protein kinase C theta immunostaining. Lee HE; Kim MA; Lee HS; Lee BL; Kim WH J Clin Pathol; 2008 Jun; 61(6):722-9. PubMed ID: 18381383 [TBL] [Abstract][Full Text] [Related]
2. KIT-negative gastrointestinal stromal tumor of the abdominal soft tissue: a clinicopathologic and genetic study of 10 cases. Yamamoto H; Kojima A; Nagata S; Tomita Y; Takahashi S; Oda Y Am J Surg Pathol; 2011 Sep; 35(9):1287-95. PubMed ID: 21836495 [TBL] [Abstract][Full Text] [Related]
3. Gastrointestinal stromal tumors presenting as omental masses--a clinicopathologic analysis of 95 cases. Miettinen M; Sobin LH; Lasota J Am J Surg Pathol; 2009 Sep; 33(9):1267-75. PubMed ID: 19440146 [TBL] [Abstract][Full Text] [Related]
4. Gastrointestinal stromal tumours (GISTs) negative for KIT (CD117 antigen) immunoreactivity. Debiec-Rychter M; Wasag B; Stul M; De Wever I; Van Oosterom A; Hagemeijer A; Sciot R J Pathol; 2004 Apr; 202(4):430-8. PubMed ID: 15095270 [TBL] [Abstract][Full Text] [Related]
5. PDGFR expression in differential diagnosis between KIT-negative gastrointestinal stromal tumours and other primary soft-tissue tumours of the gastrointestinal tract. Rossi G; Valli R; Bertolini F; Marchioni A; Cavazza A; Mucciarini C; Migaldi M; Federico M; Trentini GP; Sgambato A Histopathology; 2005 May; 46(5):522-31. PubMed ID: 15842634 [TBL] [Abstract][Full Text] [Related]
6. KIT immunohistochemistry and mutation status in gastrointestinal stromal tumours (GISTs) evaluated for treatment with imatinib. Loughrey MB; Trivett M; Beshay V; Dobrovic A; Kovalenko S; Murray W; Lade S; Turner H; McArthur GA; Zalcberg J; Waring PM Histopathology; 2006 Jul; 49(1):52-65. PubMed ID: 16842246 [TBL] [Abstract][Full Text] [Related]
7. Diagnostic relevance of overexpressions of PKC-θ and DOG-1 and KIT/PDGFRA gene mutations in extragastrointestinal stromal tumors: a Korean six-centers study of 28 cases. Kim KH; Nelson SD; Kim DH; Choi KU; Kim SJ; Min KW; Jang KS; Paik SS; Oh YH; Chae SW; Sohn JH; Kim HJ; Cho YK; Kim BI; Park DI; Sohn CI; Oh S; Choi SH; Choi YJ; Woo HY; Park YL; Park SJ; Lee SH; Ryu S; DO SI; Kang G; Kim K; Cho YH; Pyo JS Anticancer Res; 2012 Mar; 32(3):923-37. PubMed ID: 22399613 [TBL] [Abstract][Full Text] [Related]
8. Monoclonal antibody DOG1.1 shows higher sensitivity than KIT in the diagnosis of gastrointestinal stromal tumors, including unusual subtypes. Liegl B; Hornick JL; Corless CL; Fletcher CD Am J Surg Pathol; 2009 Mar; 33(3):437-46. PubMed ID: 19011564 [TBL] [Abstract][Full Text] [Related]
9. Gastrointestinal stromal tumors (GISTs): CD117, DOG-1 and PKCθ expression. Is there any advantage in using several markers? Ríos-Moreno MJ; Jaramillo S; Pereira Gallardo S; Vallejo A; Mora M; García-Escudero A; Amérigo J; González-Cámpora R Pathol Res Pract; 2012 Feb; 208(2):74-81. PubMed ID: 22197035 [TBL] [Abstract][Full Text] [Related]
10. Diagnostic significance of DOG-1 and PKC-θ expression and c-Kit/PDGFRA mutations in gastrointestinal stromal tumours. Wang C; Jin MS; Zou YB; Gao JN; Li XB; Peng F; Wang HY; Wu ZD; Wang YP; Duan XM Scand J Gastroenterol; 2013 Sep; 48(9):1055-65. PubMed ID: 23862765 [TBL] [Abstract][Full Text] [Related]
11. Analysis of mutation and expression of c-kit and PDGFR-alpha gene in gastrointestinal stromal tumor. Zheng S; Chen LR; Wang HJ; Chen SZ Hepatogastroenterology; 2007 Dec; 54(80):2285-90. PubMed ID: 18265649 [TBL] [Abstract][Full Text] [Related]
12. Kinase mutations and imatinib mesylate response for 64 Taiwanese with advanced GIST: preliminary experience from Chang Gung Memorial Hospital. Yeh CN; Chen TW; Lee HL; Liu YY; Chao TC; Hwang TL; Jan YY; Chen MF Ann Surg Oncol; 2007 Mar; 14(3):1123-8. PubMed ID: 17195905 [TBL] [Abstract][Full Text] [Related]
13. The location of KIT and PDGFRA gene mutations in gastrointestinal stromal tumours is site and phenotype associated. Penzel R; Aulmann S; Moock M; Schwarzbach M; Rieker RJ; Mechtersheimer G J Clin Pathol; 2005 Jun; 58(6):634-9. PubMed ID: 15917417 [TBL] [Abstract][Full Text] [Related]
14. [Expression and gene mutation of phospho-platelet derived growth factor receptor alpha and C-kit in gastrointestinal and extra-gastrointestinal stromal tumors]. Tang M; Li DQ Zhonghua Wei Chang Wai Ke Za Zhi; 2008 Jan; 11(1):80-3. PubMed ID: 18197502 [TBL] [Abstract][Full Text] [Related]
15. An immunohistochemical and molecular study of gastrointestinal stromal tumours. Teong YT; Teo ST; Tan LP; Wu BQ; Peh SC Med J Malaysia; 2006 Dec; 61(5):526-33. PubMed ID: 17623951 [TBL] [Abstract][Full Text] [Related]
16. Changing phenotype of gastrointestinal stromal tumours under imatinib mesylate treatment: a potential diagnostic pitfall. Pauwels P; Debiec-Rychter M; Stul M; De Wever I; Van Oosterom AT; Sciot R Histopathology; 2005 Jul; 47(1):41-7. PubMed ID: 15982322 [TBL] [Abstract][Full Text] [Related]
17. Correlation of immunophenotype with progression-free survival in patients with gastrointestinal stromal tumors treated with imatinib mesylate. Chirieac LR; Trent JC; Steinert DM; Choi H; Yang Y; Zhang J; Patel SR; Benjamin RS; Raymond AK Cancer; 2006 Nov; 107(9):2237-44. PubMed ID: 16998931 [TBL] [Abstract][Full Text] [Related]
19. Genetic and pathologic characteristics of gastrointestinal stromal tumors in extragastric lesions. Cho S; Kitadai Y; Yoshida S; Tanaka S; Yoshihara M; Yoshida K; Chayama K Int J Mol Med; 2006 Dec; 18(6):1067-71. PubMed ID: 17089009 [TBL] [Abstract][Full Text] [Related]
20. Prognostic role of E2F1 and members of the CDKN2A network in gastrointestinal stromal tumors. Haller F; Gunawan B; von Heydebreck A; Schwager S; Schulten HJ; Wolf-Salgó J; Langer C; Ramadori G; Sültmann H; Füzesi L Clin Cancer Res; 2005 Sep; 11(18):6589-97. PubMed ID: 16166437 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]